The Barbara Ann Karmanos Cancer Institute, headquartered in Detroit, is the largest cancer research and provider network in Michigan and has 16 treatment locations. It is one of 51 National Cancer Institute-designated comprehensive cancer treatment and research centers in the United States.

There are 123 beds in Karmanos cancer Center.

During the past decade, Karmanos cancer Center conducted 41 clinical trials. In the 10-year time frame, 41 clinical trials started and 19 clinical trials were completed, i.e. on average, 46.3% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 15 clinical trials were completed. i.e. 115.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Karmanos cancer Center" #1 sponsor was "Hoffmann-La Roche" with 9 trials, followed by "Novartis Pharmaceuticals" with 8 trials sponsored, "Alnylam Pharmaceuticals" with 2 trials sponsored, "Bristol-Myers Squibb" with 2 trials sponsored and "CSL Behring" with 2 trials sponsored. Other sponsors include 43 different institutions and companies that sponsored additional 49 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Karmanos cancer Center" #1 collaborator was "National Cancer Institute (NCI)" with 6 trials as a collaborator, "Blood and Marrow Transplant Clinical Trials Network" with 3 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 3 trials as a collaborator, "Astellas Pharma Inc" with 2 trials as a collaborator and "Bristol-Myers Squibb" with 2 trials as a collaborator. Other collaborators include 16 different institutions and companies that were collaborators in the rest 24 trials.

According to Clinical.Site data, the most researched conditions in "Karmanos cancer Center" are "Breast Cancer" (5 trials), "Prostate Cancer" (5 trials), "Cancer" (4 trials), "Solid Tumors" (4 trials) and "Multiple Myeloma" (3 trials). Many other conditions were trialed in "Karmanos cancer Center" in a lesser frequency.

Most popular intervention types in "Karmanos cancer Center" are "Drug" (65 trials), "Biological" (9 trials), "Other" (3 trials), "Behavioral" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (5 trials), "Placebo" (5 trials), "Cyclophosphamide" (4 trials), "Docetaxel" (3 trials) and "Enzalutamide" (3 trials). Other intervention names were less common.

The vast majority of trials in "Karmanos cancer Center" are 60 trials for "All" genders, 9 trials for "Male" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Karmanos cancer Center". undefined are not yet recruiting, 9 are recruiting, 15 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 33 completed trials in Karmanos cancer Center, 1 suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in Karmanos cancer Center, 34 "Phase 1" clinical trials were conducted, 27 "Phase 2" clinical trials and 15 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 2 trials that are defined as “Not Applicable".